Cue Biopharma, Inc.

Cue Biopharma's stockholders approved the 2026 Stock Incentive Plan at a Special Meeting held on June 1, 2026. Additionally, stockholders approved the issuance of common stock upon the exercise of warrants issued in May 2026, which were connected to a licensing transaction and related private placement. Both key proposals received sufficient votes for approval.

Cue Biopharma, Inc. announced significant changes to its Board of Directors and executive leadership. Four directors mutually agreed to resign, while Daniel Camardo and Viola Meehan were appointed as new directors, leading to a reduction in the Board's size from seven to five members. Additionally, Sumita Ray was appointed Chief Legal & Compliance Officer and Corporate Secretary, and Michael Meluzio was named Vice President, Principal Accounting Officer.

Cue Biopharma announced a significant board transition, with four independent directors resigning and two new independent directors, Daniel Camardo and Viola Meehan, appointed. This strategic change aims to support the company's growth and transformation towards late clinical stage capabilities. Camardo brings extensive commercial leadership experience, including successful launches of blockbuster medicines, while Meehan offers broad expertise in strategic finance and corporate operations. The new appointments are expected to drive patient and shareholder value as the company advances its pipeline.

Cue Biopharma, Inc. announced that its President and CEO, Shao-Lee Lin, will present at the Jefferies Global Healthcare Conference on June 3, 2026. The presentation will cover the company's progress in developing transformative therapies for immunological disorders, including its lead anti-IgE antibody in Phase 2 development and its autoimmune candidate CUE-401 advancing towards Phase 1. A live webcast and replay will be available for investors.

Cue Biopharma, Inc. is holding a Special Meeting of Stockholders on June 1, 2026, to seek approval for the issuance of up to 4,642,632 shares of common stock. This issuance is in connection with a May 2026 licensing transaction for Ascendant-221 and a related private placement that generated approximately $30 million in gross proceeds. Shareholders will also vote on the Cue Biopharma, Inc. 2026 Stock Incentive Plan. The potential share issuance represents 142% of the company's outstanding common stock, necessitating stockholder approval under Nasdaq Listing Rules.

Cue Biopharma reported a reduced net loss of $(5.178) million for the first quarter of 2026, a significant improvement from $(12.257) million in the prior year, driven by a substantial increase in collaboration revenue to $5.686 million. Despite this, the company's recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern. However, Cue Biopharma subsequently secured $27.6 million in net proceeds from a private placement in May 2026 to support future operations.

Cue Biopharma reported Q1 2026 financial results, including revenue of $5.7 million and a net loss of $5.2 million. The company announced the appointment of Shao-Lee Lin as President, CEO, and Board Director, and strengthened its financial position with a $30 million private placement and a $7.5 million milestone payment from Boehringer Ingelheim. Additionally, Cue Biopharma enhanced its pipeline by exclusively licensing CUE-221, a Phase 2 program for allergic disease, and outlined upcoming clinical milestones for CUE-221 and CUE-401 in the second half of 2026.

Cue Biopharma announced the appointment of Shao-Lee Lin, M.D., Ph.D., as its new President and Chief Executive Officer. The company granted inducement equity awards to Dr. Lin and six other new employees on May 3, 2026. These awards, made under the 2026 Inducement Stock Incentive Plan, were approved by independent directors as a material inducement for their employment.

Cue Biopharma, Inc. announced a private placement (PIPE financing) with accredited investors, expecting to raise approximately $30 million in gross proceeds. The company will sell pre-funded warrants to purchase up to 2,727,272 shares and accompanying common stock warrants to purchase up to 1,363,636 shares, at an effective price of $11.00 per unit. The net proceeds are intended to advance the company's clinical pipeline, including the acquisition and development of Ascendant-221, as well as for working capital and general corporate purposes. The financing is expected to close around May 4, 2026, pending customary closing conditions and stockholder approval.

Cue Biopharma, Inc. announced an exclusive license agreement with Ascendant Health Sciences Ltd. to develop, manufacture, and commercialize Ascendant-221, a Phase 2 clinical stage anti-IgE monoclonal antibody for allergic diseases. Cue will pay an upfront license fee of $15 million, with potential additional payments up to $676.5 million upon achieving various development, regulatory, and commercial milestones, plus tiered royalties on future sales. The agreement grants Cue global rights excluding mainland China, Hong Kong, Macau, and Taiwan. Ascendant-221 is currently in a Phase 2 study in chronic spontaneous urticaria (CSU) in China, with results expected in 2H 2026, after which Cue plans to initiate a global Phase 2b trial in food allergy.